Rovaldi Christopher
Insider CIK 1706040 · XLRN SVP, Program Mgmt and Ops · KROS Chief Operating Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | A Award | 2025-02-18 | 2025-02-19 | 60,000 | — | $0 | 60,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-15 | 150,000 | — | $0 | 150,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2023-02-16 | 2023-02-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| KROS Keros Therapeutics, Inc. | M Exercise deriv | 2022-04-06 | 2022-04-08 | 1,728 | — | $0 | 8,002 | SEC↗ |
| KROS Keros Therapeutics, Inc. | M Exercise | 2022-04-06 | 2022-04-08 | 1,728 | $16.00 | $27.6K | 1,728 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-06 | 2022-04-08 | 1,728 | $65.00 | $112.3K | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | M Exercise deriv | 2022-04-01 | 2022-04-05 | 864 | — | $0 | 9,730 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-01 | 2022-04-05 | 105 | $58.83 | $6.2K | 0 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-01 | 2022-04-05 | 366 | $57.97 | $21.2K | 105 | SEC↗ |
| KROS Keros Therapeutics, Inc. | M Exercise | 2022-04-01 | 2022-04-05 | 864 | $16.00 | $13.8K | 864 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-01 | 2022-04-05 | 2 | $54.34 | $109 | 862 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-01 | 2022-04-05 | 104 | $56.20 | $5.8K | 758 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2022-04-01 | 2022-04-05 | 287 | $56.89 | $16.3K | 471 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2022-02-01 | 2022-02-03 | 100,000 | — | $0 | 100,000 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2018-04-03 | 2018-04-04 | 600 | $39.02 | $23.4K | 25,858 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2018-04-03 | 2018-04-04 | 2,900 | $38.27 | $111.0K | 26,458 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award deriv | 2018-03-01 | 2018-03-05 | 24,375 | — | $0 | 24,375 | SEC↗ |
| XLRN ACCELERON PHARMA INC | A Award | 2018-03-01 | 2018-03-05 | 4,063 | — | $0 | 28,764 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise deriv | 2018-01-12 | 2018-01-17 | 11,000 | — | $0 | 12,000 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2018-01-12 | 2018-01-17 | 11,000 | $45.00 | $495.0K | 24,701 | SEC↗ |
| XLRN ACCELERON PHARMA INC | M Exercise | 2018-01-12 | 2018-01-17 | 11,000 | $24.11 | $265.2K | 35,701 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2018-01-03 | 2018-01-04 | 833 | $42.45 | $35.4K | 24,701 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2018-01-02 | 2018-01-04 | 1,433 | $42.41 | $60.8K | 25,534 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2017-09-12 | 2017-09-14 | 12,735 | $38.32 | $488.0K | 28,232 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2017-09-12 | 2017-09-14 | 100 | $39.96 | $4.0K | 26,967 | SEC↗ |
| XLRN ACCELERON PHARMA INC | S Sale | 2017-09-12 | 2017-09-14 | 1,165 | $39.30 | $45.8K | 27,067 | SEC↗ |